MedTrace Logo

Intralesional Bevacizumab Injection on Primary Pterygium

NCT01380678 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2011-07-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate that intralesional injection of bevacizumab on primary pterygium can reduce the corneal pterygium area, inflammation, redness and other symptoms.

Conditions

Interventions

DRUG

Intralesional injection of bevacizumab

single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day

DRUG

Topical antihistamine and vasoconstrictor

combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%

Sponsors & Collaborators

  • Khon Kaen University

    lead OTHER

Principal Investigators

  • Olan Suwan-apichon, md · Khon Kaen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Thailand

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01380678 on ClinicalTrials.gov